GSK: Statement - Zantac Litigation - Valadez and Williams Cases
May 24, 2024
May 24, 2024
LONDON, England, May 24 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on May 23, 2024:
GSK plc (LSE/NYSE: GSK) welcomes today's jury verdict in the Valadez case in Illinois state court finding in GSK's favour in the first Zantac case to go to trial. This outcome is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer, supported by 16 epi . . .
GSK plc (LSE/NYSE: GSK) welcomes today's jury verdict in the Valadez case in Illinois state court finding in GSK's favour in the first Zantac case to go to trial. This outcome is consistent with the scientific consensus that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer, supported by 16 epi . . .